Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax

Venetoclax (ABT-199), a specific inhibitor of the anti-apoptotic protein Bcl-2, is currently in phase I clinical trials for multiple myeloma. Results suggest that venetoclax is only active in a small cohort of patients therefore we wanted to determine its efficacy when used in combination. Combining...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Leukemia
Glavni autori: Matulis, Shannon M., Gupta, Vikas A., Nooka, Ajay K., Von Hollen, Hayley, Kaufman, Jonathan L., Lonial, Sagar, Boise, Lawrence H.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4874660/
https://ncbi.nlm.nih.gov/pubmed/26707935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.350
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items